Vimarsana
Biggest News Aggregation in the World

Page 16 - Cell Engineering News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Cell Engineering. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Cell Engineering Today - Breaking & Trending Today

Researchers receive $8.9 million grant to study the gut-brain connection in Parkinson's disease - Vimarsana News

Researchers receive $8.9 million grant to study the gut-brain connection in Parkinson's disease

Dr. Michael Kaplitt, a professor of neurological surgery at Weill Cornell Medicine and a longtime leader in developing cutting-edge surgical therapies for movement disorders, leads a team that has been awarded a three-year, $8.9 million grant from the Aligning Science Across Parkinson's (ASAP) initiative.

$9M grant funds study of gut-brain connection in Parkinson's - Vimarsana News

$9M grant funds study of gut-brain connection in Parkinson's

Dr. Michael Kaplitt, a professor of neurological surgery at Weill Cornell Medicine and a longtime leader in developing cutting-edge surgical therapies

Immunology and Allergology Centre to be established in Belarus - Vimarsana News

Immunology and Allergology Centre to be established in Belarus

The Immunology and Allergology Centre will be established on the basis of Belarus’ National Academy of Sciences, following a decision made...

Source: sb.by
Gut-Brain Connection Research Gets Boost of $8.9 Million - Vimarsana News

Gut-Brain Connection Research Gets Boost of $8.9 Million

Johns Hopkins Medicine researchers share in grant to study the impact of the gut on the development of Parkinson’s disease Johns Hopkins Medicine is

Belarus to roll out pilot batch of its COVID-19 vaccine in 2022 - Vimarsana News

Belarus to roll out pilot batch of its COVID-19 vaccine in 2022

“The first prototypes were developed in May this year; full-fledged prototypes containing substances that enhance the immune response were created at the end of June. Laboratory tests have been completed, they have shown good results. Now pre-clinical trials are underway,”Andrei Goncharov said.